Ginkgo Bioworks Intrinsic Value Calculator – Wall Street Bullish on Ginkgo Bioworks Holdings Inc, with Average “Buy” Rating
June 21, 2023
🌥️Trending News
Ginkgo Bioworks ($NYSE:DNA) Holdings Inc is a leading biotechnology company that designs and engineers organisms for use in a range of consumer products. It has recently seen a surge in popularity among Wall Street analysts, with an average rating of “Buy”. Most analysts are expecting the stock of Ginkgo Bioworks Holdings Inc to rise, indicating a positive outlook for the company. Ginkgo Bioworks has made significant strides in the biotechnology industry, using advances in synthetic biology to create innovative solutions. It has developed novel products such as vegan cheese, animal-free leather, and sustainable agricultural technologies. The company’s cutting-edge innovations have attracted the attention of investors, particularly due to its potential for high returns. Furthermore, Ginkgo Bioworks has established numerous strategic partnerships with other leading biotechnology companies. This has enabled the company to expand its reach and increase its access to new markets.
Additionally, the company has taken steps towards becoming more environmentally conscious, such as reducing its carbon emissions and investing in renewable energy sources. Overall, Ginkgo Bioworks Holdings Inc is well-positioned for continued success. With Wall Street bullish on its holdings, an average “Buy” rating, and numerous strategic partnerships, Ginkgo Bioworks is likely to see further growth in the near future.
Market Price
Wall Street analysts appear to be bullish on Ginkgo Bioworks Holdings Inc, with an average “Buy” rating across advisory firms. On Friday, GINKGO BIOWORKS stock opened at $2.0 and closed at $1.9, a 2.6% decrease from the previous closing price of $2.0. Despite this minor dip in share price, Wall Street analysts remain confident in the company’s further potential and have kept their “Buy” recommendations. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 390 | -1.72k | -440.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -322.88 | -50.82 | 95.64 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.42k | 809.62 | 0.83 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -426.1% |
| FCF Margin | ROE | ROA |
| -100.3% | -62.1% | -43.0% |
Analysis – Ginkgo Bioworks Intrinsic Value Calculator
At GoodWhale, we have been analyzing the fundamentals of GINKGO BIOWORKS and have found that the stock is undervalued by 65.8%. Our proprietary Valuation Line analysis has determined that the intrinsic value of GINKGO BIOWORKS is around $5.6 per share. However, the stock is currently trading at only $1.9, presenting a great opportunity for investors to buy in at a discounted rate. With our analysis, investors can be sure to make an informed decision on whether to invest in GINKGO BIOWORKS. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Analysts have a positive outlook on Ginkgo Bioworks Holdings Inc, giving it an average Buy rating. Investors should consider researching and analyzing the stock before investing, taking into account the company’s financials, market trends, and competitive landscape. Additionally, investors should stay up to date on the company’s news and developments, as these can have a significant impact on the stock’s performance. It is also important to look at the company’s fundamentals such as cash flow, return on equity, and debt levels, as these can be key indicators of how the company is doing and may influence future performance.
